News

Neonatal vancomycin trial found loading with more frequent dosing over shorter time comparable to standard regimen but adversely affected hearing.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Urban areas in Florida had more social disorganization factors that drove HIV incidence than rural areas.

Health officials in Mississippi reported a sharp increase in COVID-19-associated deaths among pregnant women during after the Delta variant became predominant.

The FDA granted an Emergency Use Authorization to Evusheld, AstraZeneca’s long-acting monoclonal antibodies for COVID-19 prevention in high-risk individuals.

For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.

A case series observation study found a slightly higher risk of Guillain-Barre syndrome among Medicare beneficiaries within 42 days after receiving the recombinant zoster vaccine Shingrix, but no changes are needed to guidance recommending the vaccine, investigators said.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

DARE-BV1, a gel that treats bacterial vaginosis, was granted FDA approval on its Prescription Drug User Fee Act (PDUFA) date today.

Merck announced an enrollment pause in 2 of their stage 3 clinical trials for once-monthly oral islatravir for HIV PrEP. Enrolled participants will continue receiving study medicine.

New research reveals that women who test positive for COVID-19 at the time they give birth pass along antibodies in breast milk, protecting their newborns from infection

The results are likely specific to areas without hypervirulent strains of Clostridioides difficile, such as Australia.

Parents who were themselves vaccinated against COVID-19 were more likely to vaccinate their children than parents who were not, yet even vaccinated parents showed some hesitancy.

Methamphetamine use and experienced intimate partner violence led to increased HIV viral replication in Black and Latinx men who have sex with men.

High-titer convalescent plasma administered to high-risk outpatients within a week of symptom onset didn’t prevent disease progression, according to a new study.

The recall involves 2 lots of 100 mg of remdesivir for injection to the user level.

The agency said the 2 monoclonal antibodies could be used to treat mild to moderate COVID-19 in all younger pediatric patients, including newborns.

A new study looked at COVID-19 related stressors and healthcare experiences, like facing discrimination, fear of perinatal infection, birth preparedness stress, telehealth prenatal care, disruptions to prenatal care, birth satisfaction, and duration of hospitalization and how these factors affected vaccination.

Hospital-onset CDI rates dropped by 6% in the first quarter of the program, which launched in 2016.

Higher ACE2 expression may explain why elderly people experience more severe COVID-19.

A study released tonight found 6 COVID-19 booster shots increased immunity for individuals who received a full 2 doses of the AstraZeneca or Pfizer-BioNTech vaccines.

The strategies address booster doses, travel, and rapid response.

Only 1 in 3 heterosexually active adults is aware of HIV PrEP, and this is even lower among Hispanic/Latinx men and women.

Study authors from the CDC found that girls in the sub-Saharan country of Namibia are at increased risk for HIV acquisition and also experience risk factors that make them eligible for HIV infection prevention programs.

The first Omicron COVID-19 case was discovered in California. The patient, who traveled from South Africa, has since recovered.

Even after it was confirmed safe, women living with HIV are neglecting to use the drug dolutegravir, potentially subjecting them to worse HIV treatment outcomes.

Rates of sustained viral suppression among people living with HIV were lower than expected, especially among children and adolescents.

After the intervention, more patients were correctly prescribed nPEP and more follow-up visits were recommended.

If the FDA authorizes molnupiravir based on the Antimicrobial Drugs Advisory Committee's recomendation, it would become the first oral COVID-19 treatment.